Concomitant infusion of unmodified donor bone marrow into unconditioned recipients of intestinal allografts by Fontes, P et al.
CLINICAL EVENTS 
Concomitant Infusion of Unmodified Donor Bone Marrow Into 
Unconditioned Recipients of Intestinal Allografts 
P. Fontes, A.S. Rao, J. Reyes, H. Furukawa, K. Abu-Elmagd, N. Jabbour, A. Zeevi, A. Iyengar, S. Todo, 
J.J. Fung, and T.E. Starzl 
TECHNICAL improvements and the advent of Tacroli-
mus, a potent immunosuppressive agent, have made 
small bowel transplantation (SBTx) a clinical reality. De-
spite the initial encouraging results. the necessity for pro-
tracted use of high doses of immunosuppression (IS) to 
prevent intestinal allograft rejection was associated with a 
surge of infectious complications and posttransplant Iym-
phoproliferative disease (PTLD) in these recipients. This 
prompted us to terminate this clinical trial at the end of 
1994 after an accrual of 63 patients l and to intensify our 
efforts to ascertain an alternative strategy that would allow 
more successful SBTx. We have previously established that 
perioperative infusion of donor bone marrow (BM) to 
whole organ allograft recipients leads to augmentation of 
chimerism and an increased incidence of donor-specific 
hyporeactivity.2 These observations have encouraged us to 
reactivate the SBTx trial with simultaneous infusion of 
unmodified donor BM. Reported herein is the clinical 
outcome of the first seven study and three control patients. 
4 MATERIALS AND METHODS 
Patients 
Since January l1J1J5. seven nonconditioned recipients have heen 
simultaneously transplanted with 6 x 10M unmodified donor BM 
cells/kg hody weight and isolated small intestine (SI. n = 3). 
combined liver and SI (n = 3) and liver and small bowel and 
pancreas (n = I). The mean recipient age was 17 :: 12 years 
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(pediatric n = 5; adult n = 2) with a follow-up ranging from 107 to 
270 d). The unavailability for consent to retrieve cadaveric donor 
BM resulted in the accrual of three patients with a mean age of 
3.3 :: 4.1 years who were monitored as contemporaneous controls. 
Following transplantation. all patients were maintained on routine 
IS with Tacrolimus and steroids with azathioprine and OKTI being 
reserved for the treatment of steroid-resistant rejection. Prophy-
lactic therapy with gancyclovir and Cytogam was restricted to 
cytomegalovirus (CMV)-negative recipients of allografts from 
CMV-positive donors. To monitor rejection. protocol endoscopic 
biopsies of the intestinal allografts were performed weekly in the 
first month and monthly thereafter. 
Bone Marrow Cell Isolation and In Vitro Studies 
BM cells were isolated from the vertebral hodies of the cadaveric 
donor by a method described elsewhere.: Pre and serially post 
transplant (every other month) ill I'itro studies were performed 
using the peripheral hlood mononuclear cells (PMBC) of the 
recipients to detect chimerism (by flow cYlometry and PCR) and to 
determine their immune status (hy MLR. LDA. recall antigens. 
ConA and PHA). These methods have been detailed elsewhere.2 
RESULTS AND DISCUSSION 
The infusion of BM was uneventful with no complications 
uniquely attributable to concomitant donor cell infusion. 
None of the augmented patients exhibited any evidence of 
graft vs host disease (GVHD). Two patients in the study 
group died on POD 19 and 60 due to respiratory and 
multi-system organ failure. respectively. One BM-aug-
mented recipient also lost his graft to intractable rejection 
and enterectomy on POD 19. Of the remaining four study 
patients. three have had total parenteral nutrition (TPN) 
discontinued and are home hound. One BM and multivis-
ceral recipient remains hospitalized with partial TPN sup-
port. All of the three control patients arc alive. two being 
TPN-free ,lOd home hound. Additionally. the incidence and 
severity of rejection was comparable in both groups. 
When tested for chimerism. donor cells were detected in 
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the PBMC of all five BM-augmented and three control 
patients at the last sample tested; however, the levels were 
much higher in the study as compared to that in the control 
patients. Due to short post operative follow-up, results of 
serial immune monitoring were inconclusive. From these 
observations we conclude that adjuvant BM infusion in 
intestinal allograft recipients is safe and is not associated 
with an increased incidence of GVHD and/or rejection. We 
are accruing more patients in this study and hope that a 
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longer follow-up in a larger cohort of recipients may 
elucidate the beneficial effects of augmented chimerism 
following adjuvant BM infusion. 
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